GHB

Discovery

GHB was first synthesized in 1874, but systematic investigation began when French biochemist Henri Laborit explored it in 1960 as a blood-brain barrier-permeable structural analog of GABA.^[1] His goal was to study inhibitory brain signaling directly — GABA itself cannot cross the barrier. Early clinical work tested GHB as an anesthetic and a potential treatment for narcolepsy and alcohol dependence.^[10]

Clinical and cultural significance

In the 1980s, GHB appeared in American health food stores as a bodybuilding and sleep supplement, driven by evidence that bedtime doses doubled growth hormone secretion.^[11] Recreational use expanded through the 1990s,^[10] and GHB gained infamy for its role in drug-facilitated sexual assault — its colorless, near-odorless liquid form and amnesia-producing properties made covert administration hard to detect. In the United Kingdom, GHB was designated a Class C controlled substance in 2003.^[12]

Prohibition and modern use

The Hillory J. Farias and Samantha Reid Date-Rape Drug prohibition Act of 2000 placed illicit GHB on US Schedule I,^[13] while sodium oxybate (Xyrem) received FDA approval for narcolepsy in 2002.^[1][2][14] In Italy and Austria, sodium oxybate (Alcover) has been approved since the 1990s for alcohol withdrawal and dependence maintenance.^[15][16] Low-sodium oxybate (Xywav) was approved for narcolepsy in 2020 and idiopathic hypersomnia in 2021.^[17]

Structure

GHB (4-hydroxybutanoic acid) is a short-chain hydroxy acid and a close structural relative of GABA, the brain's primary inhibitory neurotransmitter. The two molecules differ by a single substitution: GHB replaces GABA's amino group with a hydroxyl group.

That change gives GHB the ability to cross the blood-brain barrier — something GABA itself cannot do. GHB does not bind significantly to plasma proteins,^[4] so it moves freely in the bloodstream.

Prodrugs and precursors

Two widely available industrial chemicals function as GHB prodrugs: GBL (gamma-butyrolactone) and 1,4-BD (1,4-butanediol). GBL converts to GHB within about a minute; 1,4-BD follows a slightly longer conversion pathway.^[18] Neither is controlled under the UN Convention on Psychotropic Substances, creating a legal gap through which pharmacologically equivalent GHB exposure remains accessible.^[18]

Mechanism of action

GHB works primarily by activating GABA-B receptors — the same inhibitory receptors that baclofen targets, though at weaker potency.^[5] Blocking these receptors in animal studies eliminates GHB's sedation, hypothermia, and motor effects entirely,^[19] confirming GABA-B as the primary mechanism.

Effects escalate with dose^[5][18][3]: low concentrations produce mild neuromodulation; recreational concentrations produce sedation and muscle relaxation; overdose concentrations cause coma. A separate set of high-affinity GHB binding sites has been identified,^[8] but their function in living brain tissue remains unresolved.^[9][20]

Pharmacokinetics

GHB is taken orally; effects begin within 5–45 minutes and blood levels peak at 20–40 minutes.^[3][18] The body breaks it down through liver pathways into ordinary cellular metabolites,^[21] giving it a short half-life of 20–60 minutes^[18] and a narrow detection window — about 6 hours in blood and 10 hours in urine.^[18] Absorption and elimination both saturate at higher doses, so small increases can cause disproportionately large jumps in blood levels.^[4]

Where it acts

Endogenous GHB concentrates in the hippocampus, cortex, and the brain's dopamine-producing regions.^[22] At low concentrations it suppresses dopamine release; at higher concentrations, GABA-B activation initially suppresses dopamine neurons, but a rebound effect surge in dopamine follows as the drug clears — a mechanism thought to underlie the brief euphoric window before sedation takes hold.

GHB taken at bedtime robustly deepens slow-wave sleep and doubles growth hormone secretion.^[11] It does this by suppressing brainstem arousal centers through GABA-B activation.^[23]

Why it matters

The dopamine rebound model helps explain compulsive redosing: as the euphoric window closes, the drive to reopen it encourages another dose. GHB's ability to deepen slow-wave sleep without substantially disrupting REM has made it both a therapeutic agent and a research tool. An active Phase 2 trial (NCT06421532) is testing whether GHB-enhanced sleep can improve brain waste clearance.

Toxicity

That narrow margin exists because both absorption and elimination saturate — small dose increases push blood levels far higher than expected.^[4][5] Because GHB clears quickly (half-life 20–60 minutes), most patients recover if the airway is protected. Aspiration from vomiting while unconscious is a significant secondary risk.

Postmortem blood concentrations in GHB deaths averaged 637 mg/L but ranged from 30 to 9,200 mg/L,^[25] reflecting extreme individual variability driven by tolerance, co-ingested substances, and metabolic differences.

Psychological risks

The primary acute psychological risk is amnesia — memory suppression occurs at recreational doses^[26] and underlies GHB's use in drug-facilitated sexual assault.^[27][28] Disinhibition and impaired judgment at low doses increase risk-taking, particularly in sexual contexts.

GHB is a primary chemsex drug among men who have sex with men, with prevalence reaching 20% in some communities.^[12] Psychological dependence develops with regular use. Relapse rates exceed 60% within three months of detoxification.^[29]

Tolerance and dependence

Tolerance develops within days of continuous use through GABA-B adaptation. The precise timeline has not been established in controlled studies.citation needed

Physical dependence develops with regular use and is a significant clinical concern.^[10][7][6] GHB use disorder is described as a growing health problem in several western countries, particularly the Netherlands.^[30]

Withdrawal arrives faster than alcohol or benzodiazepine withdrawal^[6][7] and can progress rapidly from mild to severe. Initial symptoms — insomnia, anxiety, and tremor — typically resolve in 3–12 days.^[10] Severe cases escalate to delirium, psychosis, and seizures.

No FDA- or EMA-approved withdrawal protocol exists. Current approaches include:

• Benzodiazepines: first-line for symptom management, though inadequate for all cases^[31]
• Baclofen: a GABA-B agonist used as adjunct for withdrawal and relapse prevention^[32][30][12]
• Pharmaceutical GHB tapering (DeTiTap): gradual dose reduction using pharmaceutical-grade GHB, demonstrated as feasible in 23 patients in a specialist setting^[31]

Drug interactions

Alcohol combined with GHB produces additive or synergistic respiratory depression.^[3][18] Both suppress brain activity; together they push that suppression toward respiratory failure.

Opioids (including fentanyl, heroin, and methadone) add to respiratory depression through a separate mechanism — opioid receptors rather than GABA-B.^[26] This combination is associated with coma and death.

Baclofen combined with GHB produces synergistic GABA-B activation. Under medical supervision, baclofen is used to treat GHB dependence;^[12] unsupervised combination carries lethal risk.

GBL and 1,4-BD are GHB prodrugs — combining any of them with GHB effectively constitutes overdose.^[18]

Stimulants (amphetamines, cocaine, MDMA) are frequently combined with GHB in chemsex contexts.^[33] Stimulants mask GHB's sedative effects and encourage redosing; when the stimulant wears off, accumulated GHB can cause sudden overdose.

Dissociatives (ketamine, PCP) combined with GHB are flagged as lethal-severity interactions in harm reduction databases.safety citation needed Both suppress brain activity through different mechanisms; the combination is considered high-risk.

Valproate, salicylate, and phenylacetate block GHB metabolism, raising brain GHB levels.^[21]

HIV protease inhibitors (cobicistat, ritonavir) can dramatically elevate GHB plasma concentrationscitation needed — a recognized safety concern for people using GHB/GBL in chemsex contexts.

Contraindications

Concurrent CNS depressant use (alcohol, opioids, benzodiazepines, barbiturates, ketamine) is an absolute contraindication — additive respiratory depression can be lethal.^[3][18][26]

Concurrent GBL or 1,4-BD use effectively constitutes double-dosing and is an absolute contraindication.^[18]

SSADH deficiency: This rare metabolic disorder causes endogenous GHB to accumulate to dangerous levels; exogenous administration is absolutely contraindicated.

Pregnancy: No safety data exist. A single case report describes withdrawal management in a pregnant patient.^[34] Use in pregnancy is contraindicated.

Respiratory compromise: Any condition impairing breathing (COPD, sleep apnea, respiratory muscle weakness) increases the risk of GHB-induced respiratory depression.

Valproate and other GHB metabolism inhibitors: Impaired metabolism enhances effects and represents a relative contraindication.^[21]

GHB occupies an unusual dual legal position — simultaneously a Schedule I controlled substance under illicit law and a Schedule III prescription medication as sodium oxybate in the United States, a bifurcation unique in US drug policy. Internationally, GHB is controlled under Schedule IV of the UN Convention on Psychotropic Substances. The prodrugs GBL and 1,4-BD remain unscheduled in most jurisdictions, creating a persistent gap through which pharmacologically equivalent exposure remains accessible.^[18]